Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study

IF 7.4 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-09-20 DOI:10.1016/j.diabres.2025.112913

Shunsuke Kato , Ayaka Kokita , Hana Akanuma , Shogo Iwamura , Yuya Takahashi , Ryota Kusumi , Sakiko Abe , Kana Sasaki , Hitomi Otomo , Sayaka Ando , Mitsuhiko Nara , Aiko Nara , Takenobu Tadika , Tatsunori Shimizu , Takehiro Sato , Tsukasa Morii , Hiroki Fujita , Daisuke Matsuda , Hironori Waki

{"title":"Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study","authors":"Shunsuke Kato , Ayaka Kokita , Hana Akanuma , Shogo Iwamura , Yuya Takahashi , Ryota Kusumi , Sakiko Abe , Kana Sasaki , Hitomi Otomo , Sayaka Ando , Mitsuhiko Nara , Aiko Nara , Takenobu Tadika , Tatsunori Shimizu , Takehiro Sato , Tsukasa Morii , Hiroki Fujita , Daisuke Matsuda , Hironori Waki","doi":"10.1016/j.diabres.2025.112913","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>To explore how Tirzepatide (TZP) treatment influences diet-related quality of life (QoL) and thus treatment satisfaction.</div></div><div><h3>Methods</h3><div>This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP. We evaluated measurements before and after TZP treatment for clinical parameters (including BMI and HbA1c) and, via validated questionnaires, patient-reported treatment satisfaction and diet-related QoL (including the Diabetes Diet-Related Quality of Life-Revised 9 (DDRQOL-R-9)). We used Spearman correlations and multiple regression analyses to identify predictors of treatment satisfaction.</div></div><div><h3>Results</h3><div>TZP treatment led to significant reduction of median HbA1c (7.4 % to 6.4 %) and body weight (77.2 kg to 70.6 kg). Median diet-related QoL, specifically the “perceived merits of dietary therapy”, increased from 58.3 [IQR 50.0, 75.0] to 67.7 [50.0, 83.3] (p < 0.01). Multiple regression analysis identified changes in BMI (standardized β = − 0.21, p = 0.030) and changes in diet-related QoL “perceived merits of dietary therapy” (β = 0.23, p = 0.019) as independent predictors of DTSQs scores post-TZP treatment.</div></div><div><h3>Conclusion</h3><div>Despite TZP’s appetite-suppressing effects, diet-related QoL, particularly the “perceived merits of dietary therapy”, significantly increased with treatment, serving as an independent and substantial contributor to patient satisfaction, comparable to the impact of body weight reduction.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112913"},"PeriodicalIF":7.4000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822725009271","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

To explore how Tirzepatide (TZP) treatment influences diet-related quality of life (QoL) and thus treatment satisfaction.

Methods

This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP. We evaluated measurements before and after TZP treatment for clinical parameters (including BMI and HbA1c) and, via validated questionnaires, patient-reported treatment satisfaction and diet-related QoL (including the Diabetes Diet-Related Quality of Life-Revised 9 (DDRQOL-R-9)). We used Spearman correlations and multiple regression analyses to identify predictors of treatment satisfaction.

Results

TZP treatment led to significant reduction of median HbA1c (7.4 % to 6.4 %) and body weight (77.2 kg to 70.6 kg). Median diet-related QoL, specifically the “perceived merits of dietary therapy”, increased from 58.3 [IQR 50.0, 75.0] to 67.7 [50.0, 83.3] (p < 0.01). Multiple regression analysis identified changes in BMI (standardized β = − 0.21, p = 0.030) and changes in diet-related QoL “perceived merits of dietary therapy” (β = 0.23, p = 0.019) as independent predictors of DTSQs scores post-TZP treatment.

Conclusion

Despite TZP’s appetite-suppressing effects, diet-related QoL, particularly the “perceived merits of dietary therapy”, significantly increased with treatment, serving as an independent and substantial contributor to patient satisfaction, comparable to the impact of body weight reduction.

查看原文本刊更多论文

替西帕肽对2型糖尿病患者饮食相关生活质量和治疗满意度的影响：一项回顾性横断面研究

目的：探讨替西帕肽（TZP）治疗对饮食相关生活质量（QoL）及治疗满意度的影响。方法：回顾性观察研究95例2型糖尿病患者接受TZP治疗。我们评估了TZP治疗前后的临床参数（包括BMI和HbA1c），并通过有效的问卷调查，评估了患者报告的治疗满意度和饮食相关生活质量（包括糖尿病饮食相关生活质量修订9 (DDRQOL-R-9)）。我们使用Spearman相关和多元回归分析来确定治疗满意度的预测因子。结果：TZP治疗导致中位数（7.4 %至6.4 %）和体重（77.2 kg至70.6 kg）显著降低。饮食相关生活质量的中位数，特别是“饮食治疗的感知优点”，从58.3 [IQR 50.0, 75.0]增加到67.7 [50.0,83.3]（p ）结论：尽管TZP有食欲抑制作用，但饮食相关生活质量，特别是“饮食治疗的感知优点”，随着治疗而显著增加，是患者满意度的独立和重要因素，可与体重减轻的影响相媲美。(195字)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.